Marinomed Biotech announced that DKSH subsidiary Favorex has acquired commercialization rights to Marinomed’s Carragelose iota-carrageenan nasal spray for Thailand, Malaysia, Myanmar, and the Philippines. Earlier this year, Carragelose nasal spray was approved in Mexico, where it will be marketed as “Barlo” by M8. Perrigo markets the nasal spray in a number of European countries as “Physiomer Virus Defense.” The product is currently marketed in a total of 27 countries under a variety of brand names.
The company also announced that it has been granted a patent covering the use of carrageenans for the prevention and treatment of SARS-CoV-2 infection by the European Patent Office. In November 2020, Marinomed announced the initiation of a Phase 4 trial of the nasal spray agains viral respiratory infections, including COVID-19, and in March 2021, the company said that it was initiating a study of Inhaleen Carragelose iota-carageenan inhalation solution for the treatment of moderate COVID-19.
Marinomed CEO Andreas Grassauer commented, “In 2023, we could already report many good news for our Carragelose business, including the introduction of the allergen-blocking nasal spray and the moisturizing eye drops. Ending the year with a new partnership, a European patent and a successful manufacturing process shows once more that Carragelose is a success story.”
Read the Marinomed press release.
